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ABSTRACT
Mutations caused by DNA damage are a main driver of cancer. We discovered that recognition of newly
synthesised histone H4 directs breast cancer type 1 susceptibility protein (BRCA1) to post-replicative
chromatin. The switch from mutagenic to error-free DNA double strand break repair by homologous
recombination is therefore controlled by chromatin.
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DNA double strand breaks (DSBs) can be repaired by two
alternative pathways, non-homologous end joining (NHEJ)
and homologous recombination (HR). The NHEJ mechanism
fuses two DNA ends and is potentially mutagenic since small
deletions or insertions, and in the worst case, chromosomal
translocations can occur. HR on the other hand uses the genetic
information present on another homologous DNA molecule to
repair the break and is virtually error-free, as missing informa-
tion is copied from an intact template. This mechanism, how-
ever, only works if a second copy of the genetic information is
available.1 Therefore, controlling the switch from NHEJ to HR,
and linking this decision to the cell cycle, is a key challenge for
the cell as HR must only be initiated during S and G2 phases
when a second copy of the genetic material is present in the form
of a newly replicated sister chromatid.1
In humans two key players in this process are tumor
protein 53-binding protein 1 (TP53BP1, or short 53BP1),
a factor that promotes NHEJ by antagonising DNA end-
resection, and the breast cancer type 1 susceptibility protein
(BRCA1) DNA-repair complex that promotes end-resection
and thus HR.1 Cell cycle signalling is known to regulate the
transition from NHEJ in G1 to HR in S/G21. However, in
S phase the nucleus contains both, already replicated regions
that are compatible with HR, and regions that still need to be
replicated and thus should not be repaired by HR. This
enigma argues against a mechanism that solely relies on
a cell cycle switch. Until now it was elusive how the transition
between 53BP1 and BRCA1 could work at the molecular level.
Our recent work provides a simple solution to this problem
by demonstrating that the BRCA1 complex is a sensor for the
availability of a sister chromatid that signals this information
to the DNA repair machinery.2
We identified the BRCA1 complex in a screen for proteins
that distinguish between nucleosomes containing unmodified
histone H4 and H4 di-methylated at lysine 20 (H4K20me2). In
this screen BRCA1 showed a preference for H4 not methylated
at lysine 20 (H4K20me0).2 H4K20-methylation oscillates dur-
ing the cell cycle.3,4 In G1 virtually all H4K20 is di-methylated
(H4K20me2), while H4 incorporated into newly replicated
chromatin during S-phase is un-methylated (H4K20me0).
H4K20me0 thereby marks ‘new’ chromatin, and thus the pre-
sence of a sister chromatid,4 and this is sensed by BRCA1. As
a consequence, BRCA1 is recruited to post-replicative chroma-
tin in S/G2 and resides there until H4K20me0 is converted to
the mono-, di-, and tri-methylated states as the cells progress
into mitosis and divide.2 These findings lead to a strikingly
simple explanation of the cross-talk between BRCA1 and
53BP1 based on the competition between both factors on
pre- and post-replicative chromatin.
In G1 BRCA1 cannot access ‘old’ chromatin due to pervasive
H4K20me2 modification, while 53BP1 can directly bind this
mark throughout the cell cycle.5 Therefore, 53BP1’s anti-
resection activity ‘wins’ in G1 chromatin and NHEJ is initiated
as the default repair pathway. In S/G2 dilution of H4K20me2
with H4K20me0 leads to reduced 53BP1 recruitment to DSBs in
post-replicative chromatin.6,7 However, dilution alone cannot
explain the shift to HR,8 and an additional 53BP1-repressive
mechanism must exist. This activity depends on BRCA1,8 and
its recruitment to ‘new’ chromatin via H4K20me0.2
53BP1 binds H4K20me2 with rather low affinity5 and prob-
ably ‘scans’ chromatin in a dynamic fashion. At DSBs ubiqui-
tylation of histone H2A by RNF8 (RING finger protein 8) and
RNF168 (RING finger protein 168) acts as a second recruit-
ment-signal that strengthens binding of 53BP1 at the break.9
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RNF8/RNF168-dependent ubiquitylation also stimulates
BRCA1 recruitment to DSBs.10 However, BRCA1 is present
on post-replicative chromatin already before the damage
occurs.2 We envisage that the combination of reduced 53BP1
recruitment due to H4K20me2 dilution and the presence of
the competing (H4K20me0-binding) activity of BRCA1 allows
BRCA1 to accumulate at DSBs more quickly and ‘seize’ the
break before 53BP1 (Figure 1). This competition only happens
on replicated chromatin in S/G2, as the BRCA1 binding plat-
form (H4K20me0) is absent in G1. Therefore BRCA1 excludes
53BP1 and promotes end-resection specifically at DSBs in
replicated sister chromatids. The switch between NHEJ and
HR is thus determined by the rivalry between both factors for
the same binding site on histone H4 that is differentially
methylated on ‘new’ and ‘old’ histone H4.
This mechanism solves several problems at once: it targets
HR specifically to newly replicated chromatin while still allow-
ing NHEJ to occur during S-phase in un-replicated regions,
and it limits HR to S/G2 when sister chromatids are present.
The BRCA1 complex recognises H4K20me0 via the ankyrin
repeat domain (ARD) of its BARD1 (BRCA1-associated RING
domain protein 1) subunit. Indeed, mutating the histone bind-
ing site in the ARD results in loss of chromatin localisation of
BRCA1 and a shift of DSB repair during S-phase from HR to
NHEJ, as predicted.2 Our findings resolve the conundrum of
how BRCA1 ‘knows’ when to initiate HR. They also demon-
strate that in addition to the cell cycle, chromatid sensing
directs DSB repair pathway choice, and argue that the critical
decision between NHEJ and HR is made at the chromatin level
before cell cycle-regulated end resection and loading of BRCA2
(breast cancer type 2 susceptibility protein) and RAD51 (DNA
repair protein RAD51 homolog 1) take place.1
Chromatid sensing appears to be a more general mechanism
as it is employed by the TONSL/MMS22L (Tonsoku-like pro-
tein; MMS22-like protein) and SLF (SMC5-SMC6 complex
localisation factor) DNA repair complexes, in addition to
BRCA1/BARD1.2,4 All three complexes recognise H4K20me0
through subunits with ankyrin repeats.2,4 H4K20me0-binding
ARDs are potentially ‘druggable’ domains. Our findings have
therefore important clinical implications. Tumours with muta-
tions in BRCA1 are vulnerable to PARP (Poly [ADP-ribose]
polymerase) inhibitor treatment. Our study demonstrates that
H4K20me0 recognition is a central function of BARD1 in HR
and that mutating its ARD sensitises cancer cells to PARP
inhibitors.2 The development of compounds that specifically
target the BARD1 ARD and block H4K20me0 binding would
open up the possibility to chemically inactivate BRCA1 in
cancers that depend on HR due to high levels of replication
stress. These are exciting prospects for a new class of ‘epidrugs’
with the potential to benefit many cancer patients.
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Figure 1. Sister chromatid sensing by BRCA1/BARD1 directs homologous recombination to post-replicative chromatin.
Recognition of di-methylated lysine 20 of histone H4 (H4K20me2) in ‘old’ chromatin by 53BP1 (tumour protein 53-binding protein 1) and sensing of un-modified
lysine 20 of histone H4 (H4K20me0) in ‘new’ chromatin by the BRCA1 (breast cancer type 1 susceptibility protein) complex via the ankyrin repeat domain of its
BARD1 (BRCA1-associated RING domain protein 1) subunit drives a chromatin-based switch between mutagenic non-homologous end joining (NHEJ) and error-free
DNA double strand break repair by homologous recombination (HR) in pre- and post-replicative chromatin.
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